Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders' Equity

v2.4.0.8
Consolidated Statements of Changes in Stockholders' Equity (USD $)
Total
JSOP Awards [Member]
SymbioTec GmbH [Member]
Serum Institute of India Limited [Member]
Common Stock [Member]
Common Stock [Member]
JSOP Awards [Member]
Common Stock [Member]
SymbioTec GmbH [Member]
Common Stock [Member]
Serum Institute of India Limited [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
JSOP Awards [Member]
Additional Paid-in Capital [Member]
SymbioTec GmbH [Member]
Additional Paid-in Capital [Member]
Serum Institute of India Limited [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Treasury Stock [Member]
Treasury Stock [Member]
JSOP Awards [Member]
Beginning Balance at Dec. 31, 2011 $ 14,803,804       $ 922,343       $ 58,124,439       $ (43,399,413) $ (254,903) $ (588,662)  
Beginning Balance, Shares at Dec. 31, 2011         92,234,321                      
Exercise of stock options 709       195       514              
Exercise of stock options, Shares         19,535                      
Issuance of common stock   61,751 9,258,326 1,472,155   89,863 256,000 36,800   4,664,406 9,002,326 1,435,355       (4,692,518)
Issuance of common stock, Shares           8,986,281 25,600,000 3,680,000                
Share-based compensation 339,780               339,780              
Net loss (6,328,340)                       (6,328,340)      
Foreign currency translation 1,170,501                         1,170,501    
Ending Balance at Dec. 31, 2012 20,778,686       1,305,201       73,566,820       (49,727,753) 915,598 (5,281,180)  
Ending Balance, Shares at Dec. 31, 2012         130,520,137                      
Exercise of stock options 2,090       554       1,536              
Exercise of stock options, Shares         55,379                      
Share-based compensation 431,504               431,504              
Net loss (8,579,246)                       (8,579,246)      
Foreign currency translation (15,344)                         (15,344)    
Ending Balance at Dec. 31, 2013 $ 12,617,690       $ 1,305,755       $ 73,999,860       $ (58,306,999) $ 900,254 $ (5,281,180)  
Ending Balance, Shares at Dec. 31, 2013         130,575,516